Bionano Genomics, Inc.

Equities

BNGO

US09075F3055

Advanced Medical Equipment & Technology

Market Closed - Nasdaq Other stock markets 04:00:00 2024-07-09 pm EDT			5-day change	1st Jan Change
0.624 ^USD	+12.68%		+9.44%	-66.98%

Jul. 08	Bionano Genomics Raises $10 Million From Direct Offering	MT
Jul. 05	Sector Update: Health Care Stocks Advance Late Afternoon	MT

BioNano Genomics Appoints Joel Jung as Chief Financial Officer

March 11, 2014 at 08:00 am EDT

BioNano Genomics announced the appointment of Mr. Joel Jung as Chief Financial Officer. Mr. Jung has more than 17 years of experience in corporate finance and executive leadership of private and public biotech companies. Before joining BioNano Genomics, Mr. Jung was CFO of Agraquest, Inc.

Latest news about Bionano Genomics, Inc.

Bionano Genomics Raises $10 Million From Direct Offering	Jul. 08	MT
Sector Update: Health Care Stocks Advance Late Afternoon	Jul. 05	MT
Bionano Genomics to Sell Shares in Direct Offering	Jul. 05	MT
Bionano Genomics Says Revvity to Commercialize VIA Software	Jun. 20	MT
Bionano Genomics Raises $18 Million From Private Debentures Placement	May. 28	MT
Bionano Genomics, Inc. announced that it has received $18 million in funding	May. 23	CI
Bionano Genomics, Inc. Announces Significant Upgrades to its Suite of Computational Tools for Comprehensive Cancer Analysis	May. 09	CI
Transcript : Bionano Genomics, Inc., Q1 2024 Earnings Call, May 08, 2024	May. 08
Bionano Genomics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 08	CI
Bionano Genomics, Inc. Provides Revenue Guidance for the Second Quarter of 2024 and Reiterated Revenue Guidance for the Year 2024	May. 08	CI
Bionano Genomics, Hangzhou Diagens Biotechnology to Commercialize Cytogenetic Workflow for Reproductive Health	Apr. 17	MT
Bionano Genomics, Inc. and Hangzhou Diagens Biotechnology Co., Ltd. Sign Partnership to Commercialize the First Ever Clinical Cytogenetic Analysis That Combines OGM and Artificial Intelligence	Apr. 17	CI
Bionano Announces Publication Showing That Ogm Identifies Genetic Aberrations in Sarcoma Samples That May Lead to Improved Diagnosis But Were Missed by Classical Cytogenetics	Apr. 03	CI
Bionano Genomics, Inc. Announces Nine Poster Presentations and Introduces New High Throughput Stratys System at American Association for Cancer Research Annual Meeting	Apr. 02	CI
Bionano Genomics, Inc. Announces Publication of Breast Cancer Study Showing the Number of SVs Detected with OGM May be Related to Prognosis, Tumor Progression and Chemotherapy Resistance	Mar. 19	CI
Scotiabank Trims Price Target on Bionano Genomics to $6 From $7, Maintains Sector Outperform Rating	Mar. 07	MT
Bionano Genomics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 05	CI
Transcript : Bionano Genomics, Inc., Q4 2023 Earnings Call, Mar 05, 2024	Mar. 05
Bionano Genomics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Mar. 05	CI
Bionano Genomics, Inc. Provides Earnings Guidance for the First Quarter and Full Year 2024	Mar. 05	CI
Bionano Genomics, Inc. announced that it has received $35 million in funding	Feb. 26	CI
Bionano Genomics, Inc. Announces Publication of A Study That Applied Ogm to Discovery of Structural Variants Driving Drug Resistance and Sensitivity in Cancer	Jan. 25	CI
Bionano Announces Full Commercial Release of the Stratys?? System for High Throughput Optical Genome Mapping	Jan. 23	CI
Bionano Announces Peer-Reviewed Publication from its Clinical Study Designed to Support OGM as Part of Standard of Care in Genetic Disease Testing	Jan. 11	CI
Bionano Genomics, Inc. Provides Earnings Guidance for the Fourth Quarter and Full Year 2023	Jan. 08	CI

Chart Bionano Genomics, Inc.

Duration

Period

More charts

Company Profile

Bionano Genomics, Inc. is a genomics company. The Company offers optical genome mapping (OGM) solutions for applications across basic, translational and clinical research. Through Lineagen, Inc., the Company also provides diagnostic testing for patients with clinical presentations consistent with autism spectrum disorder and other neurodevelopmental disabilities. It also offers a platform-agnostic software solution, which integrates sequencing and microarray data designed to provide analysis, visualization, interpretation and reporting of copy number variants, single-nucleotide variants, and absence of heterozygosity across the genome in one consolidated view. The Company additionally offers nucleic acid extraction and purification solutions using proprietary isotachophoresis (ITP) technology. The Company markets and sells OGM systems, including the Saphyr system, which delivers OGM data to enable ultra-sensitive and ultra-specific detection of all classes of structural variation (SV).

Sector

Advanced Medical Equipment & Technology

Calendar

04:00pm - Three Molecular and Cytogenetic Associations Joint Meeting - Zhou Y.

More about the company

Income Statement Evolution

More financial data

Ratings for Bionano Genomics, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

D+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

0.624 USD

Average target price

4.933 USD

Spread / Average Target

+690.60%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Advanced Medical Equipment & Technology

	1st Jan change	Capi.
BIONANO GENOMICS, INC.	-66.98%	38.27M
THERMO FISHER SCIENTIFIC	+0.20%	205B
DANAHER CORPORATION	+3.65%	178B
INTUITIVE SURGICAL, INC.	+31.11%	158B
BOSTON SCIENTIFIC CORPORATION	+32.35%	112B
SIEMENS HEALTHINEERS AG	+1.79%	64.58B
EDWARDS LIFESCIENCES CORPORATION	+22.60%	55.34B
SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.	-3.27%	46.64B
AGILENT TECHNOLOGIES, INC.	-9.79%	36.78B
GE HEALTHCARE TECHNOLOGIES INC.	-0.58%	34.85B

Other Advanced Medical Equipment & Technology